| II-01 Noha Abdelgawad Population pharmacokinetics of pyrazinamide in hospitalised TB patients with HIV versus TB outpatients |
| II-02 Mahmoud Abdelwahab Population Pharmacokinetic/Pharmacodynamic Modelling of Clofazimine Effects on QTcF in South African tuberculosis patients |
| II-03 Leticia Arrington Evaluation of IRT-derived disease severity as a predictor of clinical success in critically ill patients with severe antibiotic resistant infections |
| II-04 Fauke Assmus Population pharmacokinetics of benznidazole as monotherapy and in combination with fosravuconazole in adult patients with chronic Chagas disease (BENDITA study) |
| II-05 Rami Ayoun Alsoud Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data |
| II-06 Irina Bondareva Population pharmacokinetics of meropenem in adult intensive care unit (ICU) patients estimated from therapeutic drug monitoring data (TDM) data |
| II-07 Unai Caballero Pharmacokinetic/pharmacodynamic modelling and simulation of the in vitro activity of isavuconazole and echinocandin combination against Candida auris. |
| II-08 Lu Chen Pharmacokinetics of fluconazole in obese and non-obese adults upon a semi-simultaneous oral and IV study design |
| II-09 Palang Chotsiri Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy |
| II-10 Selma El Messaoudi A mechanistic model to characterize the long-term dynamic of HBV markers in Lamivudine and PEG-IFNa treated patients |
| II-11 Teresa Garcia Non-linear binding model of total daptomycin in patients with normal and impaired renal function |
| II-12 Kamunkhwala Gausi Pharmacokinetics of high dose isoniazid among individuals with multidrug-resistant tuberculosis |
| II-13 Victória Etges Helfer Population pharmacokinetic modeling of ceftaroline characterizing tissue distribution following different ceftaroline fosamil infusion regimens to volunteers undergoing muscle and subcutaneous tissue microdialysis |
| II-14 Richard Höglund Pharmacokinetics and pharmacodynamics of ivermectin and its metabolites |
| II-15 Aida Kawuma Rifabutin changes dolutegravir’s half-life but not area under the curve when co-administered |
| II-16 Guillaume Lingas Lassa viral dynamics in macaques treated with favipiravir or ribavirin |
| II-17 Feiyan Liu Modeling inflammatory biomarker dynamics in human LPS challenge studies using delay differential equations |
| II-18 Nele Mueller-Plock Predicting RSV efficacy for moderate and tropical climates considering seasonal differences in RSV force-of-infection – Application of an MBMA and clinical trial simulation framework to support MK-1654 decision making |
| II-19 Anh Duc Pham Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae |
| II-20 Viktor Rognås Turn-over model characterizing effect of colistin on serum-creatinine in critically ill patients |
| II-21 Federico Romano Model-based extrapolation of the early bacterial activity (EBA) of bedaquiline-combination regimens for the treatment of pulmonary tuberculosis |
| II-22 Louis Sandra A target-mediated drug disposition model describing plasma and liver pharmacokinetics of JNJ-73763989 in AAV-HBV mice |
| II-23 Hiie Soeorg Prediction of C-reactive protein dynamics during meropenem treatment in very-low-birth-weight neonates with late-onset sepsis or pneumonia |
| II-24 Jesper Sundell Model-based characterization of drug-drug interaction between isoniazid and rifampicin |
| II-25 Lénaïg Tanneau Population pharmacokinetics of delamanid and its main metabolite DM-6705 in patients with multidrug resistant tuberculosis |
| II-26 David Uster Evaluation of four distinct weighting schemes in a model averaging and selection approach in model-informed precision dosing of continuously infused vancomycin |
| II-27 Stijn van Beek Modeling the relationship between plasma and intracellular pharmacokinetics of bedaquiline and its metabolite M2 in South African patients with rifampicin-resistant tuberculosis |
| II-28 Luka Verrest Pharmacokinetic-pharmacodynamic modelling of Leishmania blood parasite kinetics in visceral leishmaniasis patients |
| II-29 Qianwen Wang Determination of risk factors for time to culture conversion in tuberculosis patients receiving novel regimen |
| II-30 Thanaporn Wattanakul Semi-mechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria |
| II-31 Justin Wilkins PK/PD modelling of M5717 in malaria |
| II-32 Tan Zhang A population pharmacokinetic analysis to evaluate the impact of body weight, renal function, and patient status on vancomycin pharmacokinetics |
